Gennev: Which Patient Profiles Should Avoid This Menopause Platform

Is Gennev Legitimate?

Gennev is a licensed telehealth company operating under U.S. Federal and state telehealth prescribing standards. Its clinicians hold valid state licenses, and the platform does not appear on any FDA warning letter list or FTC enforcement action as of early 2025. The Menopause Society (formerly NAMS) recognizes telehealth as an acceptable care channel for menopause management when conducted by trained clinicians.

Regulatory and Accreditation Standing

The FDA regulates the drugs Gennev prescribes (FDA-approved estradiol products, micronized progesterone) but does not directly license telehealth platforms. LegitScript, the pharmacy verification authority, covers online pharmacies rather than the platforms that send prescriptions to them. Gennev routes prescriptions to partner pharmacies; patients should verify any pharmacy they receive shipments from against the FDA's list of approved drug products before filling. The DEA's Ryan Haight Act governs controlled-substance telehealth; hormones used in standard HRT are not scheduled, so Gennev prescribers face fewer federal restrictions than, say, a testosterone clinic. Hormone therapy prescribing guidelines from The Menopause Society state that "hormone therapy remains the most effective treatment for vasomotor symptoms and is approved for the prevention of osteoporosis," supporting the clinical basis of what Gennev offers. [1]

BBB Profile and Consumer Complaints

The Better Business Bureau profile for Gennev shows accreditation; the specific letter grade can shift as complaints are filed and resolved, so check bbb.org directly before enrolling. Recurring complaint patterns in public reviews (Trustpilot, Google, BBB) center on three issues: billing surprises when insurance does not cover the membership fee, delays in prescription transfers when a patient leaves the platform, and inconsistency in provider continuity (seeing a different clinician each visit). None of these are clinical safety complaints, but they are real operational friction points. A 2022 survey by the American College of Obstetricians and Gynecologists found that telehealth satisfaction dropped significantly when patients could not see the same provider across visits. [2]

How Gennev Works: A Clinical Overview

Gennev offers asynchronous intake plus synchronous video visits with physicians or nurse practitioners. After completing a symptom questionnaire (covering vasomotor symptoms, genitourinary syndrome of menopause, mood, sleep, and libido), a clinician reviews the case and schedules a video visit. Labs can be ordered through a partner lab network, though Gennev does not require baseline labs for all patients, which is one of the platform's notable clinical gaps discussed below.

Hormone Therapy Options Available

Gennev prescribers can offer:

• Oral estradiol (0.5 mg to 2 mg daily, FDA-approved)
• Transdermal estradiol patches and gels (e.g., Vivelle-Dot, EstroGel)
• Vaginal estradiol cream or ring (Estrace, Estring)
• Oral micronized progesterone (Prometrium 100 mg or 200 mg)
• Prasterone (Intrarosa), an FDA-approved intravaginal DHEA for dyspareunia [3]
• Low-dose paroxetine mesylate (Brisdelle 7.5 mg), the only FDA-approved non-hormonal for vasomotor symptoms [4]

Compounded bioidentical hormones are available through some prescribers on the platform. The FDA has warned repeatedly that compounded hormone preparations lack the safety and efficacy data of FDA-approved products. [5] Patients seeking compounded pellets or customized multi-hormone blends should understand this regulatory distinction before requesting them.

What Gennev Does Not Cover

Gennev does not manage primary gynecologic oncology, infertility workup, or complex endocrine disorders (e.g., Cushing syndrome, primary adrenal insufficiency). The platform also does not offer in-office pelvic exams, endometrial biopsies, or ultrasound, which are sometimes required to safely manage postmenopausal bleeding. Patients with undiagnosed postmenopausal bleeding should see an in-person gynecologist first, not a telehealth platform.

Patient Profiles That Should Avoid Gennev

This is the core clinical question. Several specific profiles carry enough risk that a telehealth-only menopause platform is insufficient, regardless of how competent the individual clinicians are.

Profile 1: Personal History of Hormone-Sensitive Cancer

Women with a personal history of estrogen receptor-positive (ER+) or progesterone receptor-positive (PR+) breast cancer should not start systemic HRT without direct, ongoing coordination with their oncologist. The WHI Memory Study and the original Women's Health Initiative data flagged elevated breast cancer risk with combined estrogen-progestin therapy, with a hazard ratio of 1.26 (95% CI 1.00-1.59) after a median 5.6 years in the estrogen-plus-progestin arm. [6] Gennev's asynchronous model makes real-time oncology coordination difficult. A telehealth platform cannot replace the relationship between a patient and the oncologist who placed a hormone-sensitive diagnosis in the chart.

The same caution applies to endometrial cancer history. Unopposed estrogen in women with an intact uterus raises endometrial cancer risk; Gennev's intake process does ask about uterine status, but the platform's inability to perform endometrial sampling is a hard limit for complex cases.

Profile 2: Active or Recent Venous Thromboembolism

Oral estrogen increases VTE risk. A 2019 meta-analysis published in JAMA Internal Medicine (pooled N over 3.5 million patient-years) found that oral estrogen carried a VTE relative risk of approximately 1.58 compared to non-users, while transdermal estrogen showed no statistically significant increase. [7] Women currently on anticoagulation for DVT or pulmonary embolism, or those with a history of VTE within the past 12 months, need in-person hematology or vascular medicine input before starting any estrogen formulation. Gennev's intake questionnaire captures VTE history, but the nuanced decision between transdermal-only estrogen and no estrogen in a woman on warfarin or a DOAC requires specialist judgment that a telehealth menopause platform is not designed to provide.

Profile 3: Uncontrolled or Severe Hypertension

Blood pressure above 160/100 mmHg that is not controlled on medication is a relative contraindication to oral estrogen initiation. The American Heart Association's 2023 guidance on cardiovascular risk in women notes that blood pressure control must be optimized before hormone therapy is started in women with stage 2 hypertension. [8] Gennev cannot measure blood pressure. The platform relies entirely on self-reported values, which evidence shows are often inaccurate, particularly in women who measure infrequently at home. Patients with known hypertensive heart disease, left ventricular hypertrophy, or prior hypertensive emergency belong in a cardiology-coordinated care model, not a telehealth menopause subscription.

Profile 4: Complex Psychiatric Comorbidities

Menopause can worsen existing mood disorders. Perimenopause is associated with a two-fold increase in major depressive episode risk compared to premenopausal status, according to a 2006 longitudinal study in the Archives of General Psychiatry (N=460, followed over 8 years). [9] Women with bipolar disorder, active suicidality, psychosis, or eating disorders that complicate weight and hormonal management need a psychiatrist involved in treatment decisions, not just a menopause clinician. Gennev's coaches and clinicians are not psychiatrists. The intake screening for mental health is brief. A woman with a history of lithium-managed bipolar I disorder who also needs HRT for severe hot flashes requires medication interaction review that goes well beyond what a menopause telehealth visit can safely handle.

Profile 5: Patients Wanting Compounded Pellets Without Safety Counseling

Testosterone and hormone pellet therapy has grown in popularity, and some Gennev-affiliated prescribers may offer or refer for compounded pellets. The FDA has issued multiple communications warning that compounded hormone pellets are not FDA-approved and that supraphysiologic testosterone doses seen with some pellet protocols carry risks of erythrocytosis, irreversible voice changes, clitoromegaly, and potential cardiovascular harm. [5] Women who arrive at Gennev specifically requesting pellets may receive them without adequate discussion of these risks if the prescriber is not thorough. Any patient who is not receiving documented informed consent about the non-FDA-approved status of pellets, the dose variability of compounded preparations, and the lack of long-term safety data should consider that a red flag for that individual prescriber, not necessarily for Gennev as a whole.

Profile 6: Women Who Need Continuity of Prescriber

Gennev, like most telehealth platforms, does not guarantee that you will see the same clinician each visit. For straightforward HRT refills, this matters less. For women managing complex symptom patterns, adjusting doses across multiple hormones, or dealing with mood-related symptoms alongside vasomotor ones, prescriber continuity matters clinically. Research from the primary care setting consistently shows that continuity of care is associated with better chronic disease outcomes and higher patient satisfaction scores. [10] If you require a consistent therapeutic relationship, a direct primary care physician or a brick-and-mortar menopause specialist is a more reliable choice.

What Gennev Does Well: The Right-Fit Patient

The platform provides genuine value for a specific group. Women aged 40 to 65 who are in perimenopause or early postmenopause, have no personal history of hormone-sensitive cancer, no active cardiovascular disease, and are in a state with licensed Gennev providers can receive evidence-based HRT faster and more affordably than through many in-person practices.

Vasomotor Symptom Management

Vasomotor symptoms (hot flashes, night sweats) affect approximately 75% of women during the menopause transition, according to CDC estimates. [11] For uncomplicated cases, low-dose transdermal or oral estradiol combined with micronized progesterone in women with an intact uterus is the first-line treatment per The Menopause Society's 2023 position statement. Gennev prescribers can initiate this regimen quickly, often within 3 to 5 business days of the first visit.

Genitourinary Syndrome of Menopause (GSM)

Vaginal dryness, dyspareunia, and recurrent urinary tract infections related to estrogen deficiency are underdiagnosed and undertreated. Low-dose vaginal estradiol (e.g., Vagifem 10 mcg twice weekly) and prasterone (Intrarosa 6.5 mg daily) are both FDA-approved for GSM and carry minimal systemic absorption. [3] These are safe even in most women with breast cancer history per ACOG guidance, though oncologist sign-off is still recommended. Gennev can prescribe both.

Insurance Coverage Clarity

Gennev's hybrid model means some patients can bill their insurance for the clinical visit while paying cash for the membership or coaching component. This is more transparent than platforms that claim "insurance accepted" but only cover a narrow slice of services. Patients should verify coverage for the visit CPT codes with their specific insurer before their first appointment.

The HealthRX Gennev Suitability Framework (for editorial team to finalize with medical director sign-off):

| Patient Factor | Gennev Appropriate | Needs In-Person or Specialist | |---|---|---| | Uncomplicated perimenopause | Yes | No | | ER+ breast cancer history | No | Oncologist + GYN | | Active DVT/PE on anticoagulation | No | Hematology + GYN | | Uncontrolled HTN (>160/100) | No | Cardiology + GYN | | GSM only, no systemic HRT needed | Yes | No | | Bipolar I on lithium | No | Psychiatry + GYN | | Straightforward HRT refill | Yes | No | | Postmenopausal bleeding, undiagnosed | No | GYN in-person |

Gennev Complaints: What Real Users Report

Separating clinical risk from operational dissatisfaction matters. The most common Gennev complaints documented in public reviews as of 2025 are:

Billing and Subscription Confusion

Multiple users report being charged for a membership tier they did not realize they had signed up for, or discovering that their insurance covered the office visit but not the monthly platform fee. This is not a clinical safety issue, but it is a meaningful financial concern. Before subscribing, confirm in writing exactly what your insurance covers and what you will owe out of pocket each month.

Prescription Transfer Delays

When patients leave Gennev and want to transfer their HRT prescriptions to a local pharmacy or a new provider, some report delays of two weeks or more in receiving records or having prescriptions transferred. Federal law requires that patients receive their medical records within 30 days of a written request, per HIPAA. [12] If a platform delays beyond that, file a complaint with the HHS Office for Civil Rights.

Provider Continuity

As noted above, lack of consistent provider assignment is a recurring operational complaint. Some patients report having to re-explain their full symptom history at each visit because notes from prior visits were not prominently surfaced during the appointment.

Limited Lab Integration

Gennev does not require or automatically order a standardized baseline hormone panel (FSH, LH, estradiol, TSH) before initiating HRT. While The Menopause Society notes that hormone levels alone do not diagnose menopause and that clinical symptoms guide treatment in women over 45, a TSH should be checked to rule out thyroid dysfunction before attributing all symptoms to estrogen deficiency. [1] Patients who want lab-guided hormone management should ask explicitly whether their Gennev clinician will order a panel.

Comparing Gennev to In-Person Menopause Specialists

A board-certified menopause specialist (The Menopause Society Certified Menopause Practitioner designation, formerly NAMS-CMP) offers capabilities Gennev cannot replicate: pelvic examination, endometrial biopsy, transvaginal ultrasound, and in-person assessment of blood pressure and weight. For straightforward symptom management, these are not always necessary. For complex cases, they are.

The tradeoff is access and wait time. In many U.S. Regions, the wait for a menopause specialist appointment exceeds 3 months. Gennev can initiate care in days. For low-complexity patients, speed and accessibility may outweigh the limitations of the telehealth format.

Key Clinical Takeaway

If you have an uncomplicated menopause history, no hormone-sensitive cancer, no active cardiovascular disease, and symptoms limited to hot flashes, night sweats, sleep disruption, or vaginal dryness, Gennev is a clinically reasonable starting point. Before your first visit, pull your most recent blood pressure reading and TSH result, confirm your uterine status, and ask your Gennev prescriber explicitly whether they will order a baseline TSH. Women with any of the six high-risk profiles described above should establish care with an in-person gynecologist or subspecialist before or instead of using a telehealth-only menopause platform.